The oral administration of Δ9-tetrahydrocannabinol (THC) may treat both spasticity and pain associated with multiple sclerosis.
This is according to a study being published by the journal Clinical Therapeutics, and e-published ahead of print by the U.S. National Institute of Health.
According to the Mayo Clinic, multiple sclerosis (MS) is a “disease in which the immune system eats away at the protective covering of nerves.” The ailment affects around 200,000 people annually and has no cure. Multiple sclerosis causes many different symptoms, including vision loss, pain, fatigue, and impaired coordination.
The aim of the present study was to “evaluate the efficacy of an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) in patients with progressive multiple sclerosis (MS).”